Reduced association of anti-apoptotic protein Mcl-1 with E3 ligase Mule increases the stability of Mcl-1 in breast cancer cells

British Journal of Cancer

Volumn 105, Issue 3, 2011, Pages 428-437

  Pervin, S ^a,b   Tran, A ^b   Tran, L ^b   Urman, R ^b   Braga, M ^a   Chaudhuri, G ^b   Singh, R ^a,b  

^a CHARLES R DREW UNIVERSITY OF MEDICINE AND SCIENCE   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

APOPTOSIS INHIBITOR; CASPASE; CYCLOHEXIMIDE; CYTOCHROME C; GLYCERALDEHYDE 3 PHOSPHATE DEHYDROGENASE; MITOGEN ACTIVATED PROTEIN KINASE 1; MITOGEN ACTIVATED PROTEIN KINASE 3; MULE PROTEIN; PROTEIN BCL 2; PROTEIN MCL 1; PUMA PROTEIN; RAN PROTEIN; SMALL INTERFERING RNA; UBIQUITIN PROTEIN LIGASE E3; UNCLASSIFIED DRUG;

APOPTOSIS; ARTICLE; BREAST CANCER; CANCER CELL CULTURE; CELL TRANSFORMATION; CONTROLLED STUDY; DRUG TARGETING; HUMAN; HUMAN CELL; IMMUNOPRECIPITATION; PRIORITY JOURNAL; PROTEIN DEGRADATION; PROTEIN EXPRESSION; PROTEIN PROTEIN INTERACTION; PROTEIN STABILITY; UBIQUITINATION; WESTERN BLOTTING;

APOPTOSIS REGULATORY PROTEINS; BREAST NEOPLASMS; CAENORHABDITIS ELEGANS PROTEINS; CELL CYCLE PROTEINS; CELL LINE, TUMOR; DOWN-REGULATION; EPITHELIAL CELLS; HUMANS; MACROMOLECULAR SUBSTANCES; MITOGEN-ACTIVATED PROTEIN KINASE 1; MITOGEN-ACTIVATED PROTEIN KINASE 3; PROTEIN STABILITY; PROTO-ONCOGENE PROTEINS C-BCL-2; UBIQUITIN-PROTEIN LIGASES; UBIQUITINATION;

EID: 79960839567     PISSN: 00070920     EISSN: 15321827     Source Type: Journal    
DOI: 10.1038/bjc.2011.242     Document Type: Article

References (46)

1. Abdelmohsen K, Lal A, Kim HH, Gorospe M (2007) Posttranscriptional orchestration of an anti-apoptotic program by HuR. Cell Cycle 6: 1288-1292 (Pubitemid 47327958)
2. Andersson Y, Juell S, Fodstad Ø (2004) Down regulation of the anti-apoptotic MCL-1 protein and apoptosis in MA-11 breast cancer cells induced by an anti-epidermal growth factor receptor-Pseudomonas exotoxin a immunotoxin. Int J Cancer 112: 475-483 (Pubitemid 39390614)
3. Awada A, Albanell J, Canney PA, Dirix LY, Gil T, Cardoso F, Gascon P, Piccart MJ, Baselga J (2008) Bortezomib/docetaxel combination therapy in patients with anthracycline-pretreated advanced/metastatic breast cancer: a phase I/II dose-escalation study. Br J Cancer 98: 1500-1507 (Pubitemid 351652337)
4. Bae J, Donigian JR, Hsueh AJ (2003) Tankyrase 1 interacts with Mcl-1 proteins and inhibits their regulation of apoptosis. J Biol Chem 278: 5195-5204 (Pubitemid 36801032)
5. Callagy GM, Webber MJ, Pharoah PD, Caldas C (2008) Meta-analysis confirms BCL2 is an independent prognostic marker in breast cancer. BMC Cancer 8: 153
6. Cardoso F, Ross JS, Picart MJ, Sotiriou C, Durbecq V (2004) Targeting the ubiquitin-proteasome pathway in breast cancer. Clin Breast Cancer 5: 148-157 (Pubitemid 39029208)
7. Cavo M (2007) Current status of bortezomib in the treatment of multiple myeloma. Curr Hematol Malig Rep 2: 128-137 (Pubitemid 46732570)
8. Chen D, Kon N, Li M, Zhang W, Qin J, Gu W (2005) ARF-BP1/Mule is a critical mediator of the ARF tumor suppressor. Cell 121: 1071-1083 (Pubitemid 40884397)
9. Ding Q, Huo L, Yang JY, Xia W, Wei Y, Liao Y, Chang CJ, Yang Y, Lai CC, Lee DF, Yen CJ, Chen YJ, Hsu JM, Kuo HP, Lin CY, Tsai FJ, Li LY, Tsai CH, Hung MC (2008) Down-regulation of myeloid cell leukemia-1 through inhibiting Erk/Pin 1 pathway by sorafenib facilitates chemo-sensitization in breast cancer. Cancer Res 68: 6109-6117
10. Djeu JY, Wei S (2009) Clusterin and chemoresistance. Adv Cancer Res 105: 77-92
11. Graner E, Tang D, Rossi S, Baron A, Migita T, Weinstein LJ, Lechpammer M, Huesken D, Zimmermann J, Signoretti S, Loda M (2004) The isopeptidase USP2a regulates the stability of fatty acid synthase in prostate cancer. Cancer Cell 5: 253-261 (Pubitemid 38402117)
12. Jetzt AE, Cheng JS, Tumer NE, Cohick WS (2009) Ricin A-chain requires c-Jun N-terminal kinase to induce apoptosis in nontransformed epithelial cells. Int J Biochem Cell Biol 41: 2503-2510
13. Jones MD, Liu JC, Barthel TK, Hussain S, Lovria E, Cheng D, Schoonmaker JA, Mulay S, Ayers DC, Bouxsein ML, Stein GS, Mukherjee S, Lian JB (2010) A proteasome inhibitor, bortezomib, inhibits breast cancer growth and reduces osteolysis by downregulating metastatic genes. Clin Cancer Res 16: 4978-4989
14. Kutuk O, Letai A (2008) Alteration of the mitochondrial apoptotic pathway is key to acquired paclitaxel resistance and can be reversed by ABT-737. Cancer Res 68: 7985-7994
15. Li M, Wang Y, Hung MC, Kannan P (2006) Inefficient proteasomal- degradation pathway stabilizes AP-2alpha and activates HER-2/neu gene in breast cancer. Int J Cancer 118: 802-811 (Pubitemid 43157655)
16. Liu H, Peng HW, Cheng YS, Yuan HS, Yang-Yen HF (2005) Stabilization and enhancement of the antiapoptotic activity of Mcl-1 by TCTP. Mol Cell Biol 25: 3117-3126 (Pubitemid 40464314)
17. Ludwig H, Khayat D, Giaccone G, Facon T (2005) Proteasome inhibition and its clinical prospects in the treatment of hematologic and solid malignancies. Cancer 104: 1794-1807 (Pubitemid 41513161)
18. McBride WH, Iwamoto KS, Syljuasen R, Pervan M, Pajonk F (2003) The role of the ubiquitin/proteasome system in cellular responses to radiation. Oncogene 22: 5755-5773 (Pubitemid 37176698)
19. McCubrey JA, Steelman LS, Chappell WH, Abrams SL, Wong EW, Chang F, Lehmann B, Terrian DM, Milella M, Tafuri A, Stivala F, Libra M, Basecke J, Evangelisti C, Martelli AM, Franklin RA (2007) Roles of the Raf/MEK/ERK pathway in cell growth, malignant transformation and drug resistance. Biochim Biophys Acta 1773: 1263-1284 (Pubitemid 47125967)
20. McFarlane C, Kelvin AA, de la Vega M, Govender U, Scott CJ, Burrows JF, Johnston JA (2010) The deubiquitinating enzyme USP17 is highly expressed in tumor biopsies, is cell cycle regulated, and is required for G1-S progression. Cancer Res 70: 3329-3339
21. Mei Y, Du W, Yang Y, Wu M (2005) Puma(*)Mcl-1 interaction is not sufficient to prevent rapid degradation of Mcl-1. Oncogene 24: 7224-7237 (Pubitemid 41679284)
22. Millard SM, Wood SA (2006) Riding the DUBway: regulation of protein trafficking by deubiquitylating enzymes. J Cell Biol 173: 463-468 (Pubitemid 43765193)
23. Müllauer L, Mosberger I, Grusch M, Rudas M, Chott A (2000) Fas ligand is expressed in normal breast epithelial cells and is frequently up-regulated in breast cancer. J Pathol 190: 20-30 (Pubitemid 30053349)
24. Nuñez G, Hockenbery D, McDonnell TJ, Sorensen CM, Korsmeyer SJ (1991) Bcl-2 maintains B cell memory. Nature 353: 71-73 (Pubitemid 21912458)
25. Ortiz-Ferrón G, Yerbes R, Eramo A, López-Pérez AI, De Maria R, López-Rivas A (2008) Roscovitine sensitizes breast cancer cells to TRAIL-induced apoptosis through a pleiotropic mechanism. Cell Res 18: 664-676 (Pubitemid 351793121)
26. Parsons JL, Tait PS, Finch D, Dianova II, Edelmann MJ, Khoronenkova SV, Kessler BM, Sharma RA, McKenna WG, Dianov GL (2009) Ubiquitin ligase ARF-BP1/Mule modulates base excision repair. EMBO J 28: 3207-3215
27. Pellikainen JM, Kosma VM (2007) Activator protein-2 in carcinogenesis with a special reference to breast cancer-a mini review. Int J Cancer 120: 2061-2067 (Pubitemid 46555842)
28. Pereg Y, Liu BY, O'Rourke KM, Sagolla M, Dey A, Komuves L, French DM, Dixit VM (2010) Ubiquitin hydrolase Dub3 promotes oncogenic transformation by stabilizing Cdc25A. Nat Cell Biol 12: 400-406
29. Pervin S, Singh R, Chaudhuri G (2003) Nitric-oxide-induced Bax integration into the mitochondrial membrane commits MDA-MB-468 cells to apoptosis: essential role of Akt. Cancer Res 63: 5470-5479 (Pubitemid 37139866)
30. Pervin S, Singh R, Hernandez E, Wu G, Chaudhuri G (2007) Nitric oxide in physiologic concentrations targets the translational machinery to increase the proliferation of human breast cancer cells: involvement of mammalian target of rapamycin/eIF4E pathway. Cancer Res 67: 289-299 (Pubitemid 46142787)
31. Petroski MD (2008) The ubiquitin system, disease, and drug discovery. BMC Biochem 9(Suppl 1): S7
32. Rieber M, Medina JD, Strasberg-Rieber M (2002) Relationship of Mcl-1 isoforms, ratio p21WAF1/cyclin A, and Jun kinase phosphorylation to apoptosis in human breast carcinomas. Biochem Biophys Res Commun 297: 943-949 (Pubitemid 35230342)
33. Schulte TW, Blagosklonny MV, Ingui C, Neckers L (1995) Disruption of the Raf-1-Hsp90 molecular complex results in destabilization of Raf-1 and loss of Raf-1-Ras association. J Biol Chem 270: 24585-24588
34. Sheng Y, Saridakis V, Sarkari F, Duan S, Wu T, Arrowsmith CH, Frappier L (2006) Molecular recognition of p53 and MDM2 by USP7/HAUSP. Nat Struct Mol Biol 13: 285-291 (Pubitemid 43348516)
35. Shimazu T, Degenhardt K, Nur-E-Kamal A, Zhang J, Yoshida T, Zhang Y, Mathew R, White E, Inouye M (2007) NBK/BIK antagonizes MCL-1 and BCL-XL and activates BAK-mediated apoptosis in response to protein synthesis inhibition. Genes Dev 21: 929-941 (Pubitemid 46625642)
36. Singh R, Pervin S, Karimi A, Cederbaum S, Chaudhuri G (2000) Arginase activity in human breast cancer cell lines: N(omega)-hydroxy-L-arginine selectively inhibits cell proliferation and induces apoptosis in MDA-MB-468 cells. Cancer Res 60: 3305-3312 (Pubitemid 30407931)
37. Sterz J, von Metzler I, Hahne JC, Lamottke B, Rademacher J, Heider U, Terpos E, Sezer O (2008) The potential of proteasome inhibitors in cancer therapy. Expert Opin Investig Drugs 17: 879-895 (Pubitemid 351864325)
38. Sun Y (2006) E3 ubiquitin ligases as cancer targets and biomarkers. Neoplasia 8: 645-654 (Pubitemid 44379791)
39. Thompson SJ, Loftus LT, Ashley MD, Meller R (2008) Ubiquitin-proteasome system as a modulator of cell fate. Curr Opin Pharmacol 8: 90-95 (Pubitemid 351168692)
40. Tong WG, Ding XZ, Adrian TE (2002) The mechanisms of lipoxygenase inhibitor-induced apoptosis in human breast cancer cells. Biochem Biophys Res Commun 296: 942-948
41. Wang P, Valentijn AJ, Gilmore AP, Streuli CH (2003) Early events in the anoikis program occur in the absence of caspase activation. J Biol Chem 278: 19917-19925 (Pubitemid 36799182)
42. Warr MR, Acoca S, Liu Z, Germain M, Watson M, Blanchette M, Wing SS, Shore GC (2005) BH3-ligand regulates access of MCL-1 to its E3 ligase. FEBS Lett 579: 5603-5608 (Pubitemid 41455637)
43. Wittmann S, Bali P, Donapaty S, Nimmanapalli R, Guo F, Yamaguchi H, Huang M, Jove R, Wang HG, Bhalla K (2003) Flavopiridol downregulates anti-apoptotic proteins and sensitizes human breast cancer cells to epothilone B-induced apoptosis. Cancer Res 63: 93-99 (Pubitemid 36070425)
44. Xie Y (2010) Feedback regulation of proteasome gene expression and its implications in cancer therapy. Cancer Metastasis Rev 29: 687-693
45. Yang CH, Gonzalez-Angulo AM, Reuben JM, Booser DJ, Pusztai L, Krishnamurthy S, Esseltine D, Stec J, Broglio KR, Islam R, Hortobagyi GN, Cristofanilli M (2006) Bortezomib (VELCADE) in metastatic breast cancer: pharmacodynamics, biological effects, and prediction of clinical benefits. Ann Oncol 17: 813-817
46. Zhong Q, Gao W, Du F, Wang X (2005) Mule/ARF-BP1, a BH3-only E3 ubiquitin ligase, catalyzes the polyubiquitination of Mcl-1 and regulates apoptosis. Cell 121: 1085-1095 (Pubitemid 40884398)